Heterozygous Genetic Variations of FOXP3 in Xp11.23 Elevate Breast Cancer Risk in Chinese Population via Skewed X-Chromosome Inactivation

Human Mutation

Volumn 34, Issue 4, 2013, Pages 619-628

  Zheng, Jian ^a   Deng, Jieqiong ^a   Jiang, Lan ^a   Yang, Lei ^b   You, Yonghe ^a   Hu, Min ^c   Li, Na ^a   Wu, Hongchun ^a   Li, Wei ^a   Li, Hongbin ^d   Lu, Jiachun ^b   Zhou, Yifeng ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Cancer immunity; FOXP3; Genetic susceptibility

Indexed keywords

CYTOSINE; INTERLEUKIN 10; MESSENGER RNA; S PHASE KINASE ASSOCIATED PROTEIN 2; THYMINE; TRANSCRIPTION FACTOR FOXP3;

ADULT; ALLELE; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CHEMICAL ANALYSIS; CHINESE; CHROMOSOME ANALYSIS; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; GENE FUNCTION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HETEROZYGOTE; HUMAN; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; POPULATION GENETICS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; SKEWED X CHROMOSOME INACTIVATION; T LYMPHOCYTE; X CHROMOSOME INACTIVATION;

ADULT; AGE OF ONSET; AGED; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CHINA; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RISK; RNA, MESSENGER; S-PHASE KINASE-ASSOCIATED PROTEINS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTION, GENETIC; X CHROMOSOME INACTIVATION;

EID: 84875484121     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22284     Document Type: Article

References (48)

1. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. 1992. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet 51:1229-1239.
2. Anderson CL, Brown CJ. 2002. Variability of X chromosome inactivation: effect on levels of TIMP1 RNA and role of DNA methylation. Hum Genet 110:271-278.
3. Andrieu N, Clavel F, Auquier A, Le MG, Gairard B, Piana L, Bremond A, Lansac J, Flamant R, Renaud R. 1993. Variations in the risk of breast cancer associated with a family history of breast cancer according to age at onset and reproductive factors. J Clin Epidemiol 46:973-980.
4. Bates GJ, Fox SB, Han C, Leek RD, Garcia JF, Harris AL, Banham AH. 2006. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 24:5373-5380.
5. Berendt MJ, North RJ. 1980. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 151:69-80.
6. Beyer M, Schultze JL. 2006. Regulatory T cells in cancer. Blood 108:804-811.
7. Boffetta P, Hashibe M, La Vecchia C, Zatonski W, Rehm J. 2006. The burden of cancer attributable to alcohol drinking. Int J Cancer 119:884-887.
8. Bojesen A, Hertz JM, Gravholt CH. 2011. Genotype and phenotype in Klinefelter syndrome-impact of androgen receptor polymorphism and skewed X inactivation. Int J Androl 34:e642-e648.
9. Buller RE, Sood AK, Lallas T, Buekers T, Skilling JS. 1999. Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer. J Natl Cancer Inst 91:339-346.
10. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, Goodman MT, Giuliano AE, Karanja N, McAndrew P, Hudis C, Butler J, et al. 2006. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 98:1767-1776.
11. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942-949.
12. Dossus L, McKay JD, Canzian F, Wilkening S, Rinaldi S, Biessy C, Olsen A, Tjonneland A, Jakobsen MU, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, et al. 2008. Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). Carcinogenesis 29:1360-1366.
13. El Kassar N, Hetet G, Briere J, Grandchamp B. 1998. X-chromosome inactivation in healthy females: incidence of excessive lyonization with age and comparison of assays involving DNA methylation and transcript polymorphisms. Clin Chem 44:61-67.
14. Feig SA, Hendrick RE. 1997. Radiation risk from screening mammography of women aged 40-49 years. J Natl Cancer Inst Monogr 119-124.
15. Fontenot JD, Gavin MA, Rudensky AY. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 4:330-336.
16. Gale RE, Wheadon H, Linch DC. 1991. X-chromosome inactivation patterns using HPRT and PGK polymorphisms in haematologically normal and post-chemotherapy females. Br J Haematol 79:193-197.
17. Goodfellow PJ, Mondello C, Darling SM, Pym B, Little P, Goodfellow PN. 1988. Absence of methylation of a CpG-rich region at the 5′ end of the MIC2 gene on the active X, the inactive X, and the Y chromosome. Proc Natl Acad Sci USA 85:5605-5609.
18. Hinz S, Pagerols-Raluy L, Oberg HH, Ammerpohl O, Grussel S, Sipos B, Grutzmann R, Pilarsky C, Ungefroren H, Saeger HD, Klöppel G, Kabelitz D, et al. 2007. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 67:8344-8350.
19. Hori S, Nomura T, Sakaguchi S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057-1061.
20. Jiang L, Deng J, Zhu X, Zheng J, You Y, Li N, Wu H, Lu J, Zhou Y. 2012. CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res 14:R105.
21. Jiang L, Zhang C, Li Y, Yu X, Zheng J, Zou P, Bin X, Lu J, Zhou Y. 2011. A non-synonymous polymorphism Thr115Met in the EpCAM gene is associated with an increased risk of breast cancer in Chinese population. Breast Cancer Res Treat 126:487-495.
22. Jurinke C, Oeth P, van den Boom D. 2004. MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis. Mol Biotechnol 26:147-164.
23. Karin M, Greten FR. 2005. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 5:749-59.
24. Kristiansen M, Knudsen GP, Maguire P, Margolin S, Pedersen J, Lindblom A, Orstavik KH. 2005. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer. J Med Genet 42:877-880.
25. Kristiansen M, Langerod A, Knudsen GP, Weber BL, Borresen-Dale AL, Orstavik KH. 2002. High frequency of skewed X inactivation in young breast cancer patients. J Med Genet 39:30-33.
26. Leffers N, Gooden MJ, de Jong RA, Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG, Daemen T, Nijman HW. 2009. Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother 58:449-459.
27. Li G, Su Q, Liu GQ, Gong L, Zhang W, Zhu SJ, Zhang HL, Feng YM. 2006. Skewed X chromosome inactivation of blood cells is associated with early development of lung cancer in females. Oncol Rep 16:859-864.
28. Li H, Zhou H, Zhang Q, Zhao S, Zhang Y, Wang Y, Liu J, Song Y, Yu X, Yu Y. 2011. Functional polymorphism rs7072793 C > T affect individual susceptibility to breast cancer by modulating CD25 transcription activity. Mol Carcinog.
29. Liu Y, Zheng P. 2007. FOXP3 and breast cancer: implications for therapy and diagnosis. Pharmacogenomics 8:1485-1487.
30. Long J, Cai Q, Sung H, Shi J, Zhang B, Choi JY, Wen W, Delahanty RJ, Lu W, Gao YT, Shen H, Park SK, et al. 2012. Genome-wide association study in East Asians identifies novel susceptibility Loci for breast cancer. PLoS Genet 8:e1002532.
31. Lu H. 2009. FOXP3 expression and prognosis: role of both the tumor and T cells. J Clin Oncol 27:1735-1736.
32. Medema RH, Burgering BM. 2007. The X factor: skewing X inactivation towards cancer. Cell 129:1253-1234.
33. Merlo A, Casalini P, Carcangiu ML, Malventano C, Triulzi T, Menard S, Tagliabue E, Balsari A. 2009. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27:1746-1752.
34. Pure E, Allison JP, Schreiber RD. 2005. Breaking down the barriers to cancer immunotherapy. Nat Immunol 6:1207-1210.
35. Sakaguchi S. 2004. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 22:531-562.
36. Shi Y, Hu Z, Wu C, Dai J, Li H, Dong J, Wang M, Miao X, Zhou Y, Lu F, Zhang H, Hu L, et al. 2011. A genome-wide association study identifies new susceptibility loci for non-cardia gastric cancer at 3q13.31 and 5p13.1. Nat Genet 43:1215-1218.
37. Shu XO, Long J, Lu W, Li C, Chen WY, Delahanty R, Cheng J, Cai H, Zheng Y, Shi J, Gu K, Wang WJ, et al. 2012. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 72:1182-1189.
38. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, Willer CJ, Johansen CT, Fouchier SW, et al. 2010. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466:707-713.
39. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. 2004. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 96:434-442.
40. Wu C, Hu Z, He Z, Jia W, Wang F, Zhou Y, Liu Z, Zhan Q, Liu Y, Yu D, Zhai K, Chang J, et al. 2011. Genome-wide association study identifies three new susceptibility loci for esophageal squamous-cell carcinoma in Chinese populations. Nat Genet 43:679-84.
41. Wu C, Miao X, Huang L, Che X, Jiang G, Yu D, Yang X, Cao G, Hu Z, Zhou Y, Zuo C, Wang C, et al. 2012. Genome-wide association study identifies five loci associated with susceptibility to pancreatic cancer in Chinese populations. Nat Genet 44:62-66.
42. Yager JD, Davidson NE. 2006. Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270-282.
43. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G, et al. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213.
44. Zheng J, Liu B, Zhang L, Jiang L, Huang B, You Y, Jiang Q, Zhang S, Lu J, Zhou Y. 2012. The protective role of polymorphism MKK4-1304 T>G in nasopharyngeal carcinoma is modulated by Epstein-Barr virus' infection status. Int J Cancer 130:1981-1990.
45. Zheng J, Yu X, Jiang L, Xiao M, Bai B, Lu J, Zhou Y. 2010. Association between the Cytotoxic T-lymphocyte antigen 4 +49G > A polymorphism and cancer risk: a meta-analysis. BMC Cancer 10:522.
46. Zheng Y, Rudensky AY. 2007. Foxp3 in control of the regulatory T cell lineage. Nat Immunol 8:457-462.
47. Zuo T, Liu R, Zhang H, Chang X, Liu Y, Wang L, Zheng P. 2007a. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest 117:3765-3773.
48. Zuo T, Wang L, Morrison C, Chang X, Zhang H, Li W, Liu Y, Wang Y, Liu X, Chan MW, Liu JQ, Love R, et al. 2007b. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129:1275-1286.